Skip to main content

BC Cancer – Surrey

If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

Tumour Group / Site Trial Title Opening Date
GUAndrogen Suppression with Stereotactic Body or External Beam Radiation Therapy-A Phase II Randomized Trial for Intermediate and High Risk Prostate Cancer (ASSERT)June 2016


GYNE

Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy (AZ LIGHT D0816L00003)

May 
2018
LungA Phase 3 Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant Medi4736 in Completely Resected Non-Small Cell Lung Cancer (CCTG BR.31)Sept 2015
Lung
A Phase II Randomized Study of 
Pembrolizumab in Patients with Advanced Malignant Pleural 
Mesothelioma (CCTG IND.227)
Feb 2017
Lung

A Randomized Trial of Durvalumab and Tremelimumab + Platinum Based Chemotherapy in Patients with High Risk Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC) CCTG BR.34



Lung
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU M16-298 AbbVie)
Feb 2018
LymphomaBiology of Lymphoid Cancer (Lymphoid Study)Jan 2014
Melanoma

A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) CCTG ME.13


July 2017
Myeloma
Randomized, open label, multicenter study assessing the clinical benefit
 of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone
versus carfilzomib with dexamethasone in patients with relapsed and/or
refractory multiple myeloma previously treated with 1 to 3 prior lines (Sanofi IKEMA)

June 2018
Myeloma
A Randomized Phase II, Open Label,Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma (MCRN 004)

March 2018
 You can view a video on participating in clinical trials that was created by staff at BC Cancer's Fraser Valley Centre.
http://learn.phsa.ca/bcca/clinicaltrials/2012oct23/ClinicalTrials2012oct23_flv_loader.html

SOURCE: BC Cancer – Surrey ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2018 Provincial Health Services Authority